{"id":"NCT00527904","sponsor":"POZEN","briefTitle":"A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)","officialTitle":"A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 in Subjects Who Are at Risk for Developing NSAID-associated Ulcers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2007-09-11","resultsPosted":"2010-08-20","lastUpdate":"2010-08-31"},"enrollment":239,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Ulcer"],"interventions":[{"type":"DRUG","name":"PN400 (VIMOVO)","otherNames":["Naprosyn","Nexium"]},{"type":"DRUG","name":"PN 400 (VIMOVO)","otherNames":["Naprosyn","Nexium"]}],"arms":[{"label":"PN 400 (VIMOVO)","type":"EXPERIMENTAL"}],"summary":"This study uses an open-label design and will be conducted in approximately 60 sites aiming to enroll a total number of 200 subjects to ensure that at least 100 subjects will have 12 months exposure to PN400 (VIMOVO).","primaryOutcome":{"measure":"Number of Subjects Monitored for Long-term Safety of PN 400","timeFrame":"12 months","effectByArm":[{"arm":"PN400 (VIMOVO)","deltaMin":239,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["21319944"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":239},"commonTop":["Dyspepsia","Constipation","Upper respiratory tract infection","Nausea","Arthralgia"]}}